Modality
Gene Therapy
MOA
WEE1i
Target
TROP-2
Pathway
Autophagy
SCLCASCLL
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
Jun 2020
→ Sep 2029
Phase 1Current
NCT05739683
685 pts·SCLC
2020-06→2029-09·Completed
685 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-173.5y awayPh2 Data· SCLC
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Complet…
Catalysts
Ph2 Data
2029-09-17 · 3.5y away
SCLC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05739683 | Phase 1/2 | SCLC | Completed | 685 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 |